Secnidazole 2g granules sachets

Abstract Background Bacterial vaginosis (BV) is one of the common vaginal infections among childbearing women. The usual treatment for BV is metronidazole; hence 30% of women have recurrence within 60 to 90 days after treatment. There are some studies which assessed the effect of secnidazole on BV. The aim of this systematic review was to investigate the effectiveness of secnidazole for treatment of BV. Methods The Cochrane Library, MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018) were searched. Primary outcomes were clinical cure rate and microbiologic cure rate and the secondary outcomes were adverse events. Data was extracted from eligible studies by two review authors individually and analyzed by RevMan 5.3. Results Our search found six trials involving 1528 participants. Treatment with 2 g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year by OR: 7.54 (95% CI, 3.89–14.60, p < 0.00001) and in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51–14.84, p = 0.0.008). Secnidazole (2 g) could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.63, 95% CI: 2.30–25.33, p = 0.0009) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06–382.45, p = 0.05). The clinical cure rate, microbiological effect and the therapeutic cure rate of 2 g secnidazole was significantly more than that of 1 g secnidazole. The results showed that the clinical cure rate of 2 g secnidazole was not different from the following medications: metronidazole (500 mg bid for 5 days), secnidazole plus vaginal metronidazole, 2 g single dose of oral metronidazole and 2 g secnidazole plus vaginal ornidazole. Conclusion This review showed that 2 g and 1 g secnidazole were better than placebo, however, 2 g secnidazole was more effective than 1 g. Secnidazole 2 g was not different from metronidazole (500 mg bid for 5 days), or from secnidazole plus vaginal metronidazole, or 2 g single dose of oral metronidazole or from 2 g secnidazole plus vaginal ornidazole.

Abstract licence: CC BY 4.0

Abstract Background In tropical countries like India, amoebic liver abscesses (ALA) account for almost two-thirds of the reported cases of liver abscess. This study aims to compare the efficacy, tolerability, and patient satisfaction scores of three leading nitroimidazole derivatives: metronidazole (MNZ), tinidazole (TIN), and secnidazole (SEC) against amoebic liver abscesses. Material and methods This is a single-center, triple-arm randomized controlled trial study in which patients diagnosed with ALA were randomized into three treatment groups: metronidazole (MEN), tinidazole (TIN), and secnidazole (SEC). The primary outcomes observed in this study were the resolution of symptoms and signs, including fever, abdominal pain, right hypochondrium tenderness, and leukocytosis. Drug-related side effects, patient satisfaction scores, and complications like rupture of abscess, atelectasis, or pleural effusion were secondary outcomes of the study. Results A total of 150 patients were randomized equally into three MEN, TIN, and SEC groups. Drug-related side effects were reported as minimal with TNZ, while MNZ had maximum side effects and tolerability issues (p < 0.0001). Conclusion Compared to MNZ and SEC, TNZ exhibits a rapid clinical response, an early resolution of pain and fever, good tolerance with minimal side effects, and high patient satisfaction scores. Although SEC’s side effects were similar to MNZ, TIN consistently showed superior safety and efficacy compared to both. Trial registration CTRI No CTRI/2022/01/039430

Abstract licence: CC BY 4.0

A simple, rapid, economic and green analytical method was validated for the determination of secnidazole in tablets. The aim was to contribute to the green analytical chemistry since it has low use of organic solvent and low production of toxic waste. For the HPLC-UV method, the mobile phase was a mixture of purified water + 0.7 % acetic acid and ethanol (78:22, v/v), flow rate was 1.3 mL min-1 on column CN Phenomenex Luna (250 x 4.60 mm, 5 μm particle size), injection volume was 20 μL with UV detection at 318 nm and retention time of 4.26 minutes. The method was linear over the concentration range of 5-100 μg mL-1 (r = 0.9998) with limits of detection and quantitation of 0.533 e 1.615 μg mL-1, respectively. The precision of the method showed RSD less than 2 %. The accuracy determined by the average recoveries was 99.58 %. The secnidazole tablets were subjected to oxidation, acid, alkaline, neutral and photolysis degradation as stress conditions and the method was considered as indicative of stability. The method is adequate and safe to be a great alternative method in routine quality control analyzes for determination and quantification of secnidazole tablets.

Abstract licence: CC BY-NC-SA 4.0